Previous 10 | Next 10 |
Raymond James updated its list of analyst favorite stocks with a swap in the restaurant subsector. Analysts can only have one favorite idea among the stocks they cover rated Strong Buy or Outperform. Ruth's Hospitality Group ( NASDAQ: RUTH ) makes it onto the Analysts Cu...
Qiming Venture Partners closed two new China healthcare and technology funds with $3.2 billion in fresh capital, both of them at their hard cap limits. Suzhou CStone Pharma announced that Gavreto® (pralsetinib) was approved in Hong Kong to treat adult patients with RET fusion-pos...
Blueprint Medicines Publishes Inaugural Corporate Responsibility Report PR Newswire -- Report highlights efforts to deliver sustainable value to patients and communities, foster a diverse and empowered workforce, and operate with exceptional integrity -- CAMB...
Blueprint Medicines ( NASDAQ: BPMC ) said it signed strategic financing collaborations with Sixth Street and Royalty Pharma ( NASDAQ: RPRX ) for up to $1.25B. Blueprint is selling royalty rights on lung cancer drug Gavreto — marketed by Roche ȁ...
Attractive, precision oncology therapy with long patent duration added to portfolio Blueprint Medicines to receive $175 million upfront and $165 million in potential milestone payments NEW YORK, June 30, 2022 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today an...
Blueprint Medicines Announces Transformative $1.25 Billion Strategic Financing Collaborations with Sixth Street and Royalty Pharma PR Newswire Strengthens balance sheet with significant non-dilutive, low-cost capital Expands ability to bring the promise of pr...
The precision therapy company Blueprint Medicines (NASDAQ:BPMC) is trading lower in the morning hours Monday after Wells Fargo launched its coverage with an Underweight recommendation citing, among other things, a “sell the news” data readout this year. Blueprint (BPMC) plans to...
Blueprint Medicines Appoints Habib Dable to its Board of Directors PR Newswire CAMBRIDGE, Mass. , June 23, 2022 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced the appointment of Habib Dable to its board of directors. Mr...
Citi has downgraded Blueprint Medicines (NASDAQ:BPMC) to Sell from Neutral after the commercial-stage biotech announced on Thursday a shift in the primary endpoint for a pivotal trial designed to evaluate its kinase inhibitor Ayvakit in non-advanced systemic mastocytosis (SM). The swap in mai...
Blueprint Medicines (NASDAQ:BPMC) stock fell ~9% on June 9 after the company said that it will swap the objectives of a key study of its medicine Ayvakit after recommendation from the U.S. Food and Drug Administration (FDA) The company is evaluating Ayvakit (avapritinib) in a t...
News, Short Squeeze, Breakout and More Instantly...
Blueprint Medicines Corporation Company Name:
BPMC Stock Symbol:
NASDAQ Market:
Blueprint Medicines Corporation Website:
Blueprint Medicines to Report First Quarter 2024 Financial Results on Thursday, May 2, 2024 PR Newswire CAMBRIDGE, Mass. , April 18, 2024 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that it will host a live conference call and w...
Blueprint Medicines to Host Webcast and Conference Call Highlighting Emerging Opportunities for Mast Cell-Targeted Therapeutics PR Newswire -- Dr. Mariana Castells , M.D., Ph.D., a renowned researcher and clinical expert in mast cell diseases, will join members ...
2024-04-10 04:00:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...